50 results on '"Khoja, Leila"'
Search Results
2. Circulating tumour DNA (ctDNA) in metastatic melanoma, a systematic review and meta-analysis
3. Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non–Small-Cell Lung Cancer
4. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2
5. Multi-site clonality analysis uncovers pervasive heterogeneity across melanoma metastases
6. CDK4/6 inhibitors in metastatic breast cancer, a comparison of toxicity and efficacy across agents in a real-world dataset.
7. Characteristics and outcomes in patients with KRAS mutated lung adenocarcinomas: a retrospective data analysis
8. Prognostic factors for first-line therapy and overall survival of metastatic uveal melanoma: The Princess Margaret Cancer Centre experience
9. Extracellular vesicles from biological fluids as potential markers in castration resistant prostate cancer
10. Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma
11. Management of immune-related hepatitis in patients being treated with checkpoint inhibitors for metastatic melanoma, a review and case series.
12. Extracellular vesicles from biological fluids as potential biomarkers for prostate cancer
13. Management of immune-related hepatitis in patients being treated with checkpoint inhibitors for metastatic melanoma, a review and case series
14. Circulating biomarkers in hepatocellular carcinoma
15. Dabrafenib in the treatment of metastatic or unresectable melanoma
16. Guillain-Barré Syndrome following a series of novel therapies adapting the gold-standard in the era of immune priming
17. An open-label, multicenter phase I/IIa study evaluating the safety and clinical activity of clonal neoantigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON).
18. 80 - Characteristics and outcomes in patients with KRAS mutated lung adenocarcinomas: a retrospective data analysis
19. Correlation of immune-related adverse events and response from immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
20. Multi-site clonality analyses uncovers pervasive subclonal heterogeneity and branching evolution across melanoma metastases
21. An open-label, multidrug, biomarker-directed, multicentre phase II umbrella study in patients with non-small cell lung cancer, who progressed on an anti-PD-1/PD-L1 containing therapy (HUDSON).
22. Significance of baseline FDG-PET/CT scan as a method of staging regional lymph nodes in patients with operable distal oesophageal or gastroesophageal junction adenocarcinoma
23. AR Signaling and the PI3K Pathway in Prostate Cancer
24. PD-1 agent
25. Assessment of a prognostic model, PSA metrics and toxicities in metastatic castrate resistant prostate cancer using data from Project Data Sphere (PDS)
26. Malignant Bowel Obstruction in Advanced Ovarian Cancer
27. P3.02c-076 Correlation of Neutrophil to Lymphocyte Ratio (NLR) with Clinical Benefit from Checkpoint Inhibitors in Advanced Lung Cancer
28. Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients
29. The full blood count as a biomarker of outcome and toxicity in ipilimumab‐treated cutaneous metastatic melanoma
30. Adoptive cell therapy and modulation of the tumour microenvironment: new insights from ASCO 2016
31. Prognosticators of first line treatment for metastatic uveal melanoma (MUM).
32. Tumor- and class-specific patterns of immune-related adverse events (irAEs) of immune checkpoint inhibitors (ICIs): A systematic review (SR).
33. Eosinophilic Fasciitis and Acute Encephalopathy Toxicity from Pembrolizumab Treatment of a Patient with Metastatic Melanoma
34. Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial
35. Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma
36. Pembrolizumab
37. Increased Treatment-Related Toxicity Subsequent to an Anti–PD-1 Agent
38. Abstract CT226: A pilot study of adoptive cell therapy with in vitro educated MART1 T cells in combination with ipilimumab for the treatment of metastatic melanoma
39. Brain radiosurgery and ipilimumab (Ipi) in melanoma brain metastases (MBM) patients: Does an enhanced immune response induce radionecrosis (RN)?
40. Patterns of response to anti-PD1 treatment: Comparison of three radiological response criteria and effect on overall survival (OS) in metastatic melanoma patients (MM).
41. Project Data Sphere: A first look at prostate cancer including concomitant medication use, prognosis, and toxicity.
42. Project data sphere (PDS) in prostate cancer: A first look including concomitant medication use.
43. Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma
44. Evaluation of Hypertension and Proteinuria as Markers of Efficacy in Antiangiogenic Therapy for Metastatic Colorectal Cancer
45. Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma
46. Method validation of circulating tumour cell enumeration at low cell counts
47. Dosing of the First Cycle of Perioperative Chemotherapy in Resectable Gastroesophageal Cancer: a Retrospective Study of Prescribing in Obese Patients
48. Pancreatic circulating tumor cells: Where are they?
49. Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma.
50. P-0065 - Dosing of the First Cycle of Perioperative Chemotherapy in Resectable Gastroesophageal Cancer: a Retrospective Study of Prescribing in Obese Patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.